Positron Emission Tomography (PET) Study With (11C)Flumazenil to Determine Central GABAA Receptor Occupancy of AZD7325

AstraZeneca

Status and phase: Completed; Phase 1

Conditions: Anxiety

Treatments: Drug: Radioligand (11C) flumazenil; Drug: AZD7325

Study type: Interventional

Funder types: Industry

Identifiers

NCT00681720

D1140C00007

EudractCT 2007-005436-86

Details and patient eligibility

About

The study is carried out in order to determine the relationship between the dose of AZD7325 and the blood concentration of AZD7325, and to investigate to which extent AZD7325 binds to the GABAA receptors.

Enrollment: 4 patients

Sex: Male

Ages: 20 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Body Mass Index (BMI) of 18-30 kg/m2 and weight of 60-100 kg
• Clinically normal physical findings, medical history and laboratory values.

Exclusion criteria

• Clinically significant illness or clinical relevant trauma within 2 weeks before the study start.
• Intake of another investigational drug or participation in a clinical study the past 12 weeks.
• Previous participation in a PET study within the past 12 months. Suffer from claustrophobia and would be unable to undergo MRI (magnetic resonance imaging) or PET scanning.

Trial design

Primary purpose: Basic Science

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

4 participants in 1 patient group

1

Experimental group

Treatment:

Drug: AZD7325

Drug: Radioligand (11C) flumazenil